ArticleFrontiers in immunology2023

Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer.

Renhong Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.